IPSEN has announced the registration of Cabometyx (cabozantinib) by the Therapeutic Goods Administration as a second-line therapy for patients with advanced clear-cell renal cell carcinoma (RCC) who have progressive disease following prior treatment with vascular endothelial growth factor targeted therapy.
This product is an oral tyronise kinase inhibitor and is not PBS listed - for more info see ipsen.com.
The above article was sent to subscribers in Pharmacy Daily's issue from 06 Feb 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 06 Feb 18
